Abstract
Abstract
Background
Minimal residual disease (MRD), which is characterized as leukemic cells at a level below morphologic detection, has been connected to the risk of relapse in acute myeloid leukemia. In 80–90% of acute myeloid leukemia (AML) patients, the Wilms tumor (WT1) gene is overexpressed at the mRNA level. In our prospective study, a total of 55 patients were enrolled in the study. Group I involved 40 AML patients and group II involved 15 patients healthy controls. WT1 gene expression was quantified using quantitative real-time PCR on bone marrow samples from AML patients at initial diagnosis and at day 28 after induction chemotherapy, and compared to 15 healthy controls in group II. Follow up of patients for prognosis evaluation was assessed. IBM SPSS software was used to capture and analyses the data.
Results
At diagnosis, the mean WT1 transcript value in AML patients was substantially higher than the expression observed in control patient’s Bone marrow. There was no statistically relevant relationship between the onset of relapse and WT1 expression. Patients with WT1 overexpression at diagnosis had a shorter overall survival than patients with negative WT1 expression.
Conclusions
Wilms tumor 1 gene expression was found to be significantly higher in AML patients than control cases, overall, our results confirmed the prognostic significance of WT1 overexpression in AML patients. Our findings support the application of MRD in AML patients based on WT1 overexpression.
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB (2017) Measurable residual disease testing in acute myeloid leukaemia. Leukemia 31(7):1482–1490
2. Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS et al (2015) Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol 33(11):1258–1264
3. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D et al (2019) Acute myeloid Leukemia, version 3. 2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17(6):721–49
4. Cloos J, Harris JR, Janssen J, Kelder A, Huang F, Sijm G et al (2018) Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia. J Vis Exp 133:e56386
5. Tomlinson B, Lazarus HM (2017) Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making. Expert Rev Hematol 10(6):563–574